Polycystic Liver Disease in Kidney Transplant

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Polycystic Liver Disease
Interventions
DRUG

Tacrolimus

Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)

DRUG

Sirolimus

Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)

DRUG

Mycophenolate Mofetil

Mycophenolate Mofetil 750 mg twice daily

DRUG

Prednisone

Prednisone tapered to 5 mg/day by day 92

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Mayo Clinic

OTHER

NCT00934791 - Polycystic Liver Disease in Kidney Transplant | Biotech Hunter | Biotech Hunter